Shopping Cart
Remove All
Your shopping cart is currently empty
Ro 25-6981 is a potent and selective activity-dependent NMDA receptors blocker containing the NR2B subunit with IC50s of 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively. Ro 25-6981 can be used in studies about Parkinson's disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | In Stock | In Stock | |
| 5 mg | $78 | In Stock | In Stock | |
| 10 mg | $113 | In Stock | In Stock | |
| 25 mg | $188 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $86 | In Stock | In Stock |
| Description | Ro 25-6981 is a potent and selective activity-dependent NMDA receptors blocker containing the NR2B subunit with IC50s of 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively. Ro 25-6981 can be used in studies about Parkinson's disease. |
| In vivo | Ro 25-6981 (800 µg; intrathecally) shows significant analgesic effects on incision pain in rats and effectively attenuates postoperative hyperalgesia induced by remifentanil[3]. In 6-OHDA-lesioned rats, Ro 25-6981 (0.39-12.5 mg/kg; i.p.) dose-dependently induces contraversive rotations without stimulating locomotion in normal rats[4]. In male albino rats of Wistar strain, Ro 25-6981 (1 and 3 mg/kg; i.p.) exhibits activation- and age-dependent anticonvulsant action at early postnatal development and causes a significant decrease of N1–P2 amplitude at higher stimulation intensities at 3 mg/kg[5]. |
| Molecular Weight | 339.47 |
| Formula | C22H29NO2 |
| Cas No. | 169274-78-6 |
| Smiles | C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1 |
| Relative Density. | 1.116 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (265.12 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (9.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.